To determine if transient Bcl-2 overexpression can extend the time CD-NSCs remain viable in vivo, genetically modified and parental firefly luciferase- (ffluc-) expressing CD-NSCs were injected ipsilateral to preestablished U251.DsRed glioma orthotopic xenografts. The gene discussed is BCL2; the disease is central nervous system cancer.